Gsk (GLAXF) Acquisitions (2009 - 2026)
Gsk (GLAXF) recorded quarterly Acquisitions of -$1.9 billion in Q1 2026, down 3745.98% quarter-over-quarter from -$49.2 million in Q4 2025, and down 87.86% on a YoY basis from -$15.6 billion in Q1 2025.
Gsk (GLAXF) Acquisitions (2009 - 2026) Analysis & Trends
Gsk's Acquisitions history runs 15 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.
- In Q1 2026, Acquisitions fell 87.86% year-over-year to -$1.9 billion; the TTM figure through Mar 2026 stood at -$3.9 billion (up 15.3% YoY), while the FY2025 annual figure was -$2.2 billion, down 116.8% from the prior year.
- Acquisitions was -$1.9 billion for Q1 2026 at Gsk, down from -$49.2 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of -$49.2 million in Q4 2025 to a low of -$1.9 billion in Q1 2026.
- Historically, Acquisitions has averaged -$949.9 million across 5 years, with a median of -$960.1 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Acquisitions slumped 1797.91% in 2023, then soared 94.87% in 2025.
- A 5-year view of Acquisitions shows it stood at -$91.5 million in 2022, then plunged by 1797.91% to -$1.7 billion in 2023, then surged by 44.71% to -$960.1 million in 2024, then jumped by 94.87% to -$49.2 million in 2025, then sank by 3745.98% to -$1.9 billion in 2026.
- The last three Acquisitions figures came in at -$1.9 billion (Q1 2026), -$49.2 million (Q4 2025), and -$1.0 billion (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 8.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 109.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 65.00 Mn |
| 10 | Gsk | - | - | 7.76 Bn | -1.89 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.89 Bn |
| Dec 31, 2025 | -49.22 Mn |
| Mar 31, 2025 | -1.01 Bn |
| Dec 31, 2024 | -960.06 Mn |
| Mar 31, 2024 | -912.06 Mn |
| Dec 31, 2023 | -1.74 Bn |
| Dec 31, 2022 | -91.49 Mn |
| Dec 31, 2020 | -7.92 Mn |
| Sep 28, 2020 | -7.60 Mn |
| Dec 31, 2019 | -4.68 Bn |
| Sep 30, 2019 | 114.69 Mn |
| Mar 31, 2019 | -4.74 Bn |
| Dec 31, 2016 | -29.84 Mn |
| Mar 31, 2016 | -34.40 Mn |
| Dec 31, 2015 | -5.25 Bn |
| Mar 31, 2015 | -5.21 Bn |
| Dec 31, 2014 | -25.35 Mn |
| Sep 30, 2014 | -20.06 Mn |
| Dec 31, 2013 | -331.91 Mn |
| Dec 31, 2012 | -89.93 Mn |